(CRO), and all core technologies underlying Elixira are based on validated and peer-referenced scientific principles. A detailed technical feasibility report is available to prospective partners under NDA.

Developed on in vivo–proven nanotechnology and biomedical-engineering foundations, Elixira integrates self-sustaining hybrid-energy systems and multiple elimination methods to enable a proactive, continuous prevention model. Operating autonomously inside the human body, it detects, targets, and neutralizes cancer cells in real time — powered entirely by its own renewable energy systems.

Elixira is advancing toward preclinical development and has received growing international attention. The company is ranked #1 in multiple F6S categories (including Top Nanotechnology and Life Sciences Companies in Sweden, October 2025) and #11 globally among the Top 100 Nanotechnology Companies. It is also trending in Medical Device and Healthcare categories on Crunchbase, reflecting rapid momentum within the global nanomedicine ecosystem, along with record readership across Zenodo and other academic platforms for its published white papers.

Engineered for global scalability, ethical accessibility, and minimal infrastructure requirements, Elixira’s mission is to provide universal access to cancer prevention — enabled by an ethically driven licensing framework designed to make Elixira available across borders to both low-income and high-income countries alike and free to the patient.

Elixira has received strong global interest and collaboration requests from partners worldwide and is welcoming licensing partnerships, as it is currently evaluating licensing opportunities with select organizations in nanotechnology and oncology that share Elixira’s ethical and preventive mission.

General inquiries: contact@elixira.tech | Licensing inquiries: licensing@elixira.tech | Website: https://elixira.tech